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Paired Box-1 (PAX1) Activates 
Multiple Phosphatases and Inhibits 
Kinase Cascades in Cervical Cancer
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Tzu-I Wu  3,6, Michael W. Y. Chan7,8, Chi-Chun Liao2, Chien-Wen Chen2, Wei-Yu Lin  9 & 
Cheng-Chang Chang5
DNA methylation alteration, such as global hypomethylation and localized hypermethylation, within 
the promoters of tumor suppressor genes, is an important risk factor in cervical cancer. The potential 
use of DNA methylation detection, in cervical cancer screening or triage of mildly abnormal cytology, 
has recently been demonstrated. In particular, PAX1 DNA methylation testing was approved as an 
adjunct to cytology, in Taiwan, and is now undergoing registration trials in China. However, the function 
of PAX1 in cancer biology remains largely unknown. Here, we show that PAX1 inhibits malignant 
phenotypes upon oncogenic stress. Specifically, PAX1 expression inhibited the phosphorylation of 
multiple kinases, after challenges with oncogenic growth factors such as EGF and IL-6. Analogously, 
PAX1 activated a panel of phosphatases, including DUSP1, 5, and 6, and inhibited EGF/MAPK signaling. 
PAX1 also interacted with SET1B, increasing histone H3K4 methylation and DNA demethylation 
of numerous phosphatase-encoding genes. Furthermore, hypermethylated PAX1 associated with 
poor prognosis in cervical cancer. Taken together, this study reveals, for the first time, the functional 
relevance of PAX1 in cancer biology, and further supports the prospect of targeting multifold oncogenic 
kinase cascades, which jointly contribute to multiresistance, via epigenetic reactivation of PAX1.
Cervical cancer is the fourth-most common female cancer, and the fourth overall cause of cancer death, in the 
world. In 2018, there were an estimated 569,847 worldwide new cases, and 311,365 deaths1. Over 90% of deaths 
from cervical cancer occur in developing countries. However, even in developed countries, 13,240 and 62,356 
annual new cases occur in the U.S and Southeast Asia, respectively1,2.
The causative agent of cervical cancer is the human papillomavirus (HPV)3. While most HPV infections are 
transient, few cells remain persistently infected. However, HPV persistent infection is insufficient for cancer for-
mation, as the cervical epithelia must accumulate other genetic and epigenetic changes to become fully malig-
nant4. To that end, genetic alterations, such as karotypic abnormalities (e.g., gains of chromosome 3q, 5p and 
20q)5–7, amplification or activating mutations of oncogenes such as PIK3CA and EGFR, and inactivating muta-
tions of tumor suppressor genes, such as PTEN, are all common contributors to cervical cancer8–11.
In addition to genetic events, epigenetic alterations, such as DNA methylation, play a critical role in cancer 
development and progression. A hallmark of cancer cells is a global decrease in DNA methylation, and localized 
hypermethylation of the promoters of specific tumor suppressor genes12. During the past decade, genome-wide 
approaches, such as microarray and next-generation sequencing (NGS), have more comprehensively identified 
differentially methylated genes in cancers. Moreover, several clinical trials are examining DNA methylation as a 
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biomarker for cancer detection, including cervical and colon cancer13,14, with a methylation test for the advanced 
disease being approved in 2016 by the U.S. Food and Drug Administration (FDA)15.
Similar to the above, DNA methylation as a biomarker for cervical cancer early detection is also promis-
ing16–18. Cytology-based cervical cancer screening has been used for nearly a century, albeit with unsatisfactory 
sensitivity and a 20% false positive rate19. And, while a quadravalent vaccine against HPVs 5, 11, 16, and 18 has 
reduced infection by those strains, it is minimally effective against other strains, and is little available in develop-
ing nations3. To more accurately detect cervical cancer, DNA methylation, as an adjunct for cytology or human 
papilloma virus (HPV) testing, is becoming the standard for molecular cervical cancer screening13,20. The meth-
ylation of the paired box-1 (PAX1) gene in cervical cancer was firstly reported in 200816. Serial validation studies 
performed worldwide have demonstrated its potential in cervical cancer molecular screening21–24. In 2016, the 
Taiwanese FDA approved the application of PAX1 methylation as an adjunct of conventional cytology in cervical 
cancer screening25. Despite this diagnostic association with cervical cancer, however, there remains a gap in the 
mechanistic understanding of the precise role of PAX1 in disease etiology.
The PAX gene family is named for the paired box DNA-binding domain that is critical for tissue development 
and cellular differentiation in embryos26. In cancer, however, the function of PAX genes is controversial and 
has not been well characterized27. Four PAX family subgroups exist, based on their structural domains: paired 
domain, octapeptide, and homeodomain26. PAX1 and PAX9 belong to subgroup I, which has a DNA-binding 
paired domain without a homeodomain, and these show functional redundancy during embryogenesis28. PAX9 
is also amplified and highly expressed in lung cancer, and its knockdown reduced lung cancer formation in a xen-
ograft study, supporting a role in oncogenesis29. On the contrary, PAX1 was aberrantly methylated, and downreg-
ulated, in cervical, oral, and ovarian cancer, suggesting that PAX1 is a tumor suppressor gene16,30,31. Nevertheless, 
the mechanism underlying the role of the PAX gene family in cancer biology has not been elucidated. Here, we 
present the first comprehensive, functional investigation of the mechanistic role of PAX1 in cancer.
Results
PAX1 Inhibits malignant phenotypes of cervical cancer cell lines upon EGF stimulation. To 
explore the role of PAX1 in cervical carcinogenesis, we used immunohistochemical staining to examine its 
expression over the full spectrum of cervical lesions, including normal epithelium, precancerous lesions, and 
invasive cancer. The results of this experiment revealed that PAX1 nuclear expression was weak in normal cervix, 
moderate in low-grade squamous intraepithelial lesion (LSIL), strongest in high-grade squamous intraepithelial 
lesion (HSIL), but weak in invasive cancer cells (Fig. 1A,B). These data suggest that PAX1 functions as a tumor 
suppressor, especially at the transition from in situ to invasive cancer. Consequently, we overexpressed PAX1 in 
two cervical cancer cell lines, HeLa and SiHa, and found that it did not significantly inhibit malignant phenotypes, 
including proliferation, migration, and invasion, in vitro, and tumor growth, in vivo (Fig. 1C–F). However, the 
function of a tumor suppressor gene may not become obvious until the existence of oncogenic stressors, such as 
the expression of certain cytokines or growth factors. Thus, we hypothesized that PAX1 might inhibit malignant 
phenotypes in the presence of growth factors. In cervical cancer, the epidermal growth factor (EGF) was reported 
to induce the epithelial-to-mesenchymal transition (EMT), a metastasis-related phenotype that includes cancer 
cell invasion32. Hence, we examined the effects of PAX1 in the presence of EGF. As expected, PAX1 expression 
inhibited EGF-induced EMT phenotypes, including mesenchymal spindle shape, migration, and cell invasion 
(Fig. 2A–C). Analogously, we observed that the EMT marker Snail was downregulated by PAX1, while the epi-
thelial marker CDH1 was upregulated (Supplementary Fig. S1). Moreover, PAX1 significantly inhibited tumor 
growth in cells pretreated with EGF (Fig. 2D). Together, these results support our hypothesis that PAX1 is a 
tumor suppressor that is responsive to environmental factors, such as EGF, and inhibits EGF-induced EMT and 
malignant phenotypes.
PAX1 activates multiple phosphatases and inhibits EGF-mediated signaling. To examine the 
extent to which PAX1 inhibits the EGF-associated kinome, we tested for kinome changes using an array-based 
assay. The results of this experiment demonstrated that PAX1 inhibited the activity of multiple oncogenic kinases, 
including the MAPK pathway (ERK1/2 and P38), and the SRC pathway (HCK, FYN, and SRC) (Fig. 3A,C, and 
Supplementary Fig. S2A). In addition to EGF, IL-6 is another oncogenic cytokine, and its activation can induce 
STAT3 and AKT signaling, resulting in tumor growth and invasion in numerous cancers, including cervical33,34. 
Furthermore, IL-6 expression has been correlated with poor prognosis in cervical cancer35. In this context, we 
observed PAX1 to inhibit IL6-mediated activation of several oncogenic signaling kinases, such as AMPK, P70 S6 
kinase, AKT, β-catenin, and PRAS40 (Fig. 3B,C and Supplementary Fig. S2B).
ERK1/2 is most sensitive to PAX1 inhibiting its phosphorylation by about 80%. Western blotting thus con-
firmed that PAX1 delayed the timing and amplitude of ERK1/2 phosphorylation in SiHa cells (Fig. 3D). Since 
inhibition of EGF signaling may be achieved via activation of protein phosphatases, and a previous study revealed 
the protein tyrosine phosphatase, receptor type R (PTPRR), to inhibit ERK phosphorylation in cervical can-
cer17, we tested whether PTPRR is a transcriptional target of PAX1. Those results demonstrated that PTPRR was 
indeed upregulated upon PAX1 expression, especially in the presence of EGF (Supplementary Fig. S4A). Further, 
ChIP-PCR confirmed PAX1 binding to the PTPRR promoter (Supplementary Fig. S4B). These results reveal that 
PAX1-activated PTPRR inhibits the EGF signaling pathway, via inhibition of ERK1/2 phosphorylation.
As PAX1 can also inhibit multiple kinase pathways, we assessed this possibility, in a manner similar to our 
observations for PTPRR. Our analysis of gene expression profiles obtained after PAX1 expression and EGF 
stimulation (Supplementary Fig. S5A), demonstrating that 2534 genes were upregulated by PAX1, including 32 
phosphatase genes (Supplementary Fig. S5B, Fig. 4A and Supplementary Table S1). Of these, six dual-specificity 
phosphatases (DUSPs; DUSP1, DUSP4, DUSP5, DUSP6, DUSP8, and DUSP19) are known to dephosphorylate 
ERK36, and PPP2R5A, a subunit of PP2A, is known to dephosphorylate SRC37. The expression of these six DUSPs 
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was confirmed by qPCR, among which DUSP5, DUSP1, and DUSP6 were dramatically upregulated by 60-, 50-, 
and 15-fold, respectively (Fig. 4B), and PAX1 was confirmed to bind the DUSP1, DUSP5, and DUSP6 promoters 
(Supplementary Fig. S6). Gene ontology analysis also revealed that PAX1 reduced the genes for cell-cycle and 
mitosis pathways (Fig. 4C and Supplementary Table 2), further indicative of it tumor suppressor role.
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Figure 1. PAX1 slightly reduces malignant phenotypes in cervical cancer cell lines. (A) PAX1 protein 
expression in tissue samples across the full spectrum of cervical lesions. Normal, n = 19; LSIL, n = 15; HSIL, 
n = 21; and invasive carcinoma, n = 64. The scale bar represents 100 μm. The weak cytoplasmatic staining of 
PAX1 was background. (B) Scatterplot of PAX1 staining scores. **p < 0.01; ***p < 0.001. (C) In vitro growth 
curve of HeLa and SiHa cervical cancer cells in control and PAX1-overexpressing cells. Cancer cell migratory 
(D) and invasive (E) phenotypes, as assessed by wound healing and matrigel invasion assays, respectively. The 
red line in (D) indicates the migration start site. (F) In vivo tumor growth of HeLa and SiHa cells, in control and 
PAX1-overexpressing cells.
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A PAX1–WDR5–SET1B complex methylates H3K4 and activates the expression of multiple 
phosphatases. To clarify the mechanism of PAX1 activation of DUSPs, we assessed changes in histone mod-
ifications in various DUSP genes. ChIP-PCR showed that PAX1 expression increased trimethylation of histone 
H3, lysine 4 (H3K4, an activating modification), without changing H3K9 trimethylation (a repressive modi-
fication), within the PTPRR, DUSP1, DUSP5, and DUSP6 promoters (Fig. 5A–B and Supplementary Fig. S7). 
Moreover, we observed reduced levels of DNA methylation within these same promoters (Fig. 5C,D). These 
results suggest that PAX1 cooperates with H3K4 methyltransferases and/or H3K9/DNA demethylases, to dere-
press phosphatase expression.
Two major enzyme families are involved in H3K4 trimethylation in humans: the SET and MLL families. Both 
share common components, such as WDR5, but target diverse genes38. To understand how PAX1 might induce 
H3K4 trimethylation, we tested possible protein-to-protein interactions between PAX1 and components of the SET 
and MLL complexes, including SET1A, SET1B, MLL1, MLL2, MLL4, and WDR5, in addition to the DNA demeth-
ylases, TET1 and TET2. Coimmunoprecipitation assays indicated direct binding of PAX1 to SET1B and WDR5, but 
not to other H3K4 HMTs and DNA demethylases (Fig. 5E). Analogously, the reverse experiment also demonstrated 
WDR5 binding to PAX1 (Fig. 5F), which also bound the PTPRR, DUSP1, DUSP5, and DUSP6 promoters (Fig. 5G 
and Supplementary Fig. S6). Taken together, these data suggest that PAX1 activates phosphatase genes, via interact-
ing with SET1B and WDR5, to change histone modifications to a transcriptionally permissive state.
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Figure 2. PAX1 inhibits EGF-induced malignant phenotypes in cervical cancer cell lines. (A) EGF-induced 
elongation and single-cell scattering of HeLa and SiHa cells is inhibited by PAX1, as are migratory (B) and 
invasive (C) phenotypes. The red line in (B) indicates the migration start site. (D) PAX1 inhibits tumor 
formation in HeLa and SiHa cell lines pretreated with EGF, in vivo.
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PAX1 methylation associates with poor prognosis in cervical cancer. To understand further the 
status of PAX1 promoter methylation in cervical cancers, we extracted and analyzed DNA methylation profiles 
from a TCGA dataset. The median methylation levels (beta-values) of the non-tumor specimens and tumors 
were 0.05 and 0.58, respectively (Fig. 6A), while PAX1 promoter methylation levels in non-tumor tissues were 
significantly lower than those in tumors (Mann-Whitney U test, p < 0.0001). In addition, hypermethylated PAX1 
associated with poor progression-free survival (PFS), and poor overall survival (OS), in patients with cervical 
squamous cell carcinoma (Fig. 6B).
Discussion
The present study demonstrated that PAX1 plays a tumor suppressor role in response to the onset of oncogenic 
stress, including growth factor stimulation. We further demonstrated that PAX1 inhibited EGF and IL-6 signa-
ling, through epigenetic activation of multiple phosphatases (Fig. 6C). Kinase–phosphatase network is rigidly 
regulated in normal physiology39–41. The kinase cascade may reciprocally activate the phosphatase to keep growth 
signaling in check. In cancer, however, the regulation loop between kinases and phosphatases is little known. 
Our data show that PAX1 inhibits EGF–ERK signaling, via epigenetic activation of multiple phosphatases. 
Furthermore, it was reported the ERK1 mediates activation of the PAX1-like protein in Giardia lamblia42, sug-
gesting that PAX1 mediates a physiologic balance between kinases and phosphatases. Taken together, we specu-
lated that PAX1 might activate multiple phosphatases that keep oncogenic kinases in check.
Our previous study demonstrated that the methylation of PAX1 is associated with HPV L1 region methyla-
tion in the ≥CIN2 lesions25. Under nitroxidative stress, full-length HPV transformed precancerous cell lines can 
undergo epigenomic modifications including DNA methylation of an EMT inhibition phosphatase, PTPRR43. 
Indeed, there were reports demonstrating HPV infection is associated with higher nitric oxide synthase expres-
sion44 and nitric oxide (NO) concentration in cervix45, suggesting the indirect effects of HPV infection on epig-
enomics. Furthermore, the methylation of PAX1 was increased in the keratinocyte after immortalized by the 
full-length HPV1646. Together with the present study, the infection of HPV may cause the promoter methylation 
of PAX1 and result in the reduction of phosphatases’ expression. Therefore, hypermethylated PAX1 may derepress 
the oncogenic kinase cascade, thus promoting cancer progression.
Previously, the PAX family was reported to participate in development, but its role in cancer has been little 
studied. It was suggested that PAX2 and PAX5 play tumor suppressor roles in ovarian cancer and leukemia47,48, 
while conversely, PAX3, PAX7, and PAX6 were reported to be oncogenic in embryonal rhabdomyosarcomas and 
retinoblastoma49,50. However, these reports were all based only on correlations between expression and malignant 
Figure 3. PAX1 inhibits the EGF- and IL-6 mediated kinome. Kinase array revealing PAX1 inhibition of 
EGF- (A) and IL-6- (B) kinase activity, and signaling, in HeLa cells. (C) Quantitative results of PAX1-inhibited 
pathway signaling. (D) Western blot confirming decreased ERK1/2 phosphorylation by PAX1, in SiHa cells. 
GAPDH was used as loading control. Full blots are shown in Supplementary Fig. S3.
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phenotypes, and the underlying mechanisms were not investigated. Although PAX1 is known to participate in 
neuronal development51, there have been no reports of a possible role in cancer biology. Previous studies regard-
ing the PAX family and chromatin modifiers (histone deacetylases (HDACs) and histone lysine methyltrans-
ferases (HMTs)), in developmental biology, revealed interactions between PAX2 and MLL2/3 (KMT2C/D, an 
HMT), in embryonic kidney cell lines, PAX5 and HMTs/HDACs, in mouse B cell development, and PAX7 and 
HMTs, in mouse myogenesis52–55. In cancer, PAX-interacting proteins remain largely unknown. Here, we demon-
strate that PAX1 interacts with SET1B, but neither MLL1–MLL4 nor SET1A. Further, the cooperation between 
PAX1 and the SET1B histone H3K4 methyltransferase complex c activated the phosphatome and suppressed 
Figure 4. Genome-wide analysis reveals that PAX1 induces multiple phosphatases upon EGF stimulation. (A) 
Heatmap of PAX1-induced phosphatases in HeLa cell. (B) Validation of phosphatase expression by qPCR. (C) 
Gene ontology analysis of PAX1-regulated genes.
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kinase signaling. These findings represent the first indication of PAX1-modulated epigenetic regulation of the 
kinase–phosphatase loop in cancer biology.
In addition, resistance to targeted therapy in cancer is a notorious problem. For example, tyrosine kinase 
inhibitors (TKIs), designed to target mutant EGFR, have shown dramatic therapeutic efficacy in lung cancer; 
Figure 5. PAX1 regulates phosphatases’ expression by recruiting the histone methyltransferase SET1B. 
The status of histone H3K4 and H3K9 trimethylation within the PTPRR promoter in PAX1-expressing cells 
after EGF treatment. (A) HeLa- and (B) SiHa-PAX1-expressing cells. (C,D) Promoter methylation status 
of phosphatase genes, in PAX1-expressing cells, after EGF treatment. Interaction between PAX1, SET1B, 
histone H3K4 HMT, and DNA demethylases, as detected by co-IP. An anti-FLAG antibody was used for 
immunoprecipitation, and antibodies against the histone H3K4 HMT complex and DNA demethylases were 
used for blotting (E). The reverse experiment, i.e., complexes immunoprecipitated by an antibody against 
WDR5, and immunoblot for Flag (F). (G) The binding of WDR5, within the PTPRR promoter in PAX1-
expressing cells, after EGF treatment. Full blots are shown in Supplementary Figs S8 and S9.
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however, patients often develop resistance to therapy56. Additionally, compensatory oncogenic kinase cascades, 
such as the MAPK57, PI3K/AKT58, and SRC/AKT59 pathways, may render TKIs ineffective. In that regard, our 
study revealed that PAX1-activated phosphatases can inhibit multiple MAPK pathways and the SRC kinase. 
Consequently, reactivation of DNA methylation-silenced PAX1 may be a strategy to inhibit multiple oncogenic 
kinase pathways, which could reverse multi-pathway resistance to antineoplastic TKI drugs.
In conclusion, PAX1 is responsible for maintaining an on-and-off homeostasis between kinases and phos-
phatases, within the cervical epithelium. Loss of PAX1 expression, however, through DNA methylation, may 
disrupt this balance, leading to cancer development, supporting the further study of PAX1 DNA methylation as 
a biomarker for cervical cancer detection. Moreover, reactivation of PAX1 may overcome the failure of current 
target therapies targeting single kinases in cervical cancer treatment. We strongly contend that such epigenetic 
Figure 6. PAX1 promoter methylation status in cervical cancer, and association with decreased progression-
free (PFS) and overall (OS) survival. (A) Methylation status of PAX1 in cervical cancer. Displayed are the 
methylation levels of three patients, who donated both tumor and non-tumor specimens. T, tumor tissue; 
N, normal tissue. The analyzed probes were located in the CpG island (chr20:21686200-21687689) of PAX1 
promoter. (B) Kaplan–Meier plots of the probability of PFS and OS, stratified according to the methylation 
status of PAX1, in patients with cervical cancer. (C) Proposed model of PAX1-induced phosphatase expression, 
and disruption of EGF signaling.
9Scientific RepoRts |          (2019) 9:9195  | https://doi.org/10.1038/s41598-019-45477-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
therapies, and consequent reactivation of tumor suppressors, are a promising strategy for overcoming the insidi-
ous problem of cancer chemo- and targeted therapy multiresistance.
Methods
Clinical samples. Paraffin-embedded cervical tissues of Chinese patients were retrieved from the 
Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taiwan. The tissue 
microarrays comprised histologically normal squamous epithelium (n = 19), mild dysplasia (n = 15), carcinoma 
in situ (n = 21) and invasive carcinoma (n = 46). A standard protocol for immunohistochemistry was used with 
rabbit polyclonal anti-human PAX1 antibody (Abcam, ab95227). All tissue microarray slides were examined 
and scored by pathologists, according to the summation of the percentage of area stained multiplied by the stain 
intensity. All patients were diagnosed, treated, and had their tissues banked at the Tri-Service General Hospital, 
National Defense Medical Center, Taipei, Taiwan. The final diagnosis was made by tissue-proven pathology rather 
than cytology except for controls. Exclusion criteria included pregnancy, chronic or acute systemic viral infec-
tions (except HPV infection), a history of cervical neoplasia, skin or genital warts, an immunocompromised state, 
the presence of other cancers, or a history of surgery to the uterine cervix. This study was conducted in accord-
ance with the Declaration of Helsinki and approved by the Institutional Review Board of the Tri-Service General 
Hospital. All of the patients signed informed consent forms before study.
Cell lines, culture conditions, and constructs. The human cervical cancer cell lines HeLa and SiHa were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) or RPMI 1640 medium containing 10% (w/v) fetal calf 
serum, penicillin at 100 U/ml, streptomycin at 100 μg/ml, and L-glutamine at 2 mmol/l (all from Thermo Fisher 
Scientific). PAX1 (NM_006192) was constructed by inserting a full-length cDNA product into a pCMV-Tag 2B 
vector. The construct was then transfected into HeLa and SiHa cells with Lipofectamine 2000 (Thermo Fisher 
Scientific) in Opti-MEM I reduced-serum medium (Thermo Fisher Scientific) at 37 °C in a 5% CO2 atmosphere 
for 4–5 h, after which the medium was removed and replaced with fresh culture medium. Cells were selected by 
antibiotic (G418) after 2 days in culture. Control cells were transfected with pCMV-Tag 2B vector only. The con-
centration of EGF (Thermo Fisher Scientific) in culture medium in this study is 50 ng/mL.
Cell proliferation assay. Cell proliferation was measured using MTS assay (Promega) as described in our 
previous study43. Briefly, cells were seeded in 96-well plates at a density of 2000 cells/well. On days 0, 1, 2, 3, and 4, 
culture medium was replaced by fresh medium containing MTS reagent (100 µl medium plus 20 µl MTS reagent/
well). After incubation at 37 °C for 2 hours, the absorbance at 490 nm was measured. Experiments were repeated 
four times.
Cell migration assay and invasion assays. Cell migration assay and invasion assays were described in 
detail in our earlier study43. Cell migration was assessed using the scratch wound-healing assay. Cells were seeded 
into 6-well dishes until confluent and then wounded using a pipette tip. The migration area was photographed at 0 
and 24 h. Cell migration was quantified by measuring the migrated area using ImageJ. Cell invasion was measured 
in the Transwell system with Matrigel (BD Bioscience). 2000 cells were seeded in the upper chamber in culture 
medium without serum. The same medium with serum was added to the lower chamber. Cells that had perme-
ated the Matrigel and migrated to the bottom of the insert were fixed with methanol and stained with Giemsa’s 
azur eosin methylene blue solution (Merck) after 24 h. The cells in each chamber were photographed and counted.
RNA extraction, cDNA synthesis, and quantitative real-time PCR (qPCR). RNA extraction, cDNA 
synthesis, and quantitative real-time PCR were performed as described in our earlier studies17,43. Total RNA was 
isolated by Qiagen RNeasy kit with DNase I digestion (Qiagen) and reverse-transcribed to cDNA using the Super 
Script III first-strand synthesis system for RT-PCR with Oligo(dT) as the primer (Thermo Fisher Scientific). 
qPCR was performed by Roche SYBR Green Real-Time PCR System (Roche). The glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as the internal reference gene. The comparative threshold cycles (Ct) method 
was used for relative quantification. All values are expressed as mean ± SD. The primers used in this study are 
shown in Supplementary Table S3.
DNA extraction, bisulfite modification, quantitative methylation-specific PCR (qMS-PCR). 
qMS-PCR was performed as described by in our former study43. In brief, genomic DNA was extracted with the 
QIAmp DNA Mini Kit (Qiagen) and bisulfite-modified by CpGenome Fast DNA Modification Kit (Millipore). 
qMS-PCR was performed using SYBR Green Real-Time PCR System (Roche). Internal control gene was the 
type II collagen (COL2A). Samples with a crossing point-PCR-cycle (Cp) value for COL2A greater than 36 were 
defined as failure to detect. The DNA methylation level was assessed as the methylation index (M-index), 10 
000 × 2([Cp of COL2A] − [Cp of gene]. The primers used in this study are shown in Supplementary Table S4.
Chromatin immunoprecipitation assay. Chromatin immunoprecipitation (ChIP) assays were per-
formed according to the protocol from Millipore (EZ-Magna ChIP G Chromatin Immunoprecipitation Kit). 
DNA was eluted with 100 ul elution buffer, and 4 ul was used per Q-PCR analysis. Quantitative PCR was per-
formed using RT² SYBR Green qPCR Master Mixes (Qiagen) in a LightCycler 480 Real-Time PCR System 
(Roche). The antibodies used in the ChIP-PCR analysis were anti-Flag (Sigma, F1804); anti-trimethyl-Histone 
H3K4 (07-473), anti-trimethyl-Histone H3K9 (07-442) and anti-mouse IgG (12-371) were from Merck Millipore. 
The primers used in this study are shown in Supplementary Table S5.
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Immunoblot and kinase array analysis. Cells used for immunoblot were serum-starvated for 16 h and 
treated with medium with EGF for 0, 5, 15 and 30 min. The process of immunoblot were described in detail in our 
earlier study43. The antibodies used in the immunoblot analysis were: anti-phospho-ERK 1/2 (9106), anti-ERK 1/2 
(9102) from Cell Signaling; anti-Set1A (sc-515590), anti-Set1B (sc-248564), anti-MLL1 (sc-377274), anti-MLL2 
(sc-292359), anti-MLL4 (sc-517017), anti-TET2 (sc-136926), anti-TET3 (sc-139186) from Santa Cruz; anti-TET1 
(GT1462) from GeneTex. Kinome was analyzed by Human Phospho-Kinase Array Kit (ARY003B, R & D sys-
tems) according to the manufacturer’s instructions. Cells used for kinome analysis were serum starvated for 16 h 
and treated with medium with EGF or IL-6 for 15 min.
In vivo tumorigenicity model. Six-week-old nude mice were used in the tumorigenicity analysis. 106 cells 
from each stable line were resuspended in 0.1 ml PBS and injected subcutaneously into both flanks of each mouse. 
The mice were sacrificed at day 30. Tumors were removed from the mice and weighed. The protocol for this ani-
mal experiment was approved by the Institutional Animal Care and Use Committee (IACUC) of the National 
Defense Medical Centre, Taipei, Taiwan. All animal procedures and animal care were performed according to 
institutional animal research guidelines.
Global gene expression analysis. Total RNA samples were isolated and the absorbance ratio of A260/
A280 and A260/A230 analyzed by Nanodrop 2000 (Thermo Scientific) should bigger than 1.8 and 1.0, respec-
tively. The further qualification, the ratio of 28S/18S and RNA quality indicator (RQI) was analyzed by Agilent 
2100 Bioanalyzer (Agilent Technologies). Samples with ratio of 28S/18S is bigger than 1 and RQI is bigger than 7 
were send to the core service unit (Health GeneTech Corp.) for whole-genome expression analysis. We measured 
gene expression profiles using Illumina HumanHT-12 v4 Expression Beadchip (Illumina, Inc.). The data had 
been deposited in the Gene Expression Omnibus (GEO) database (GSE102986). After quantile normalization, 
we removed the probes with detecting p-values > 0.05 in all of the samples. The average of signal (AVG_signal) 
of each probe was calculated from duplication of expression data. Differentially expressed genes were identified 
as having a ≥1.25-fold change in the average expression in the PAX1-1 set and PAX1-2 set compare to EGF set 
(Supplementary Fig. S5A,B). The phosphatase gene list was obtained from the human DEPhOsphorylation data-
base (DEPOD, http://depod.bioss.uni-freiburg.de/).
Statistical analysis. The Mann-Whitney U test, two-tailed, was used to compare data groups for cell prolif-
eration, migration, invasion, and tumor formation. Standard deviations were used for error bars and various com-
parisons. Kaplan-Meier analysis and log-rank tests were used to calculate survival, and to compare differences 
between curves for progression-free survival (PFS) and overall survival (OS). p-values < 0.05 were considered to 
be statistically significant. Methylomics profiles of cervical cancer cases, obtained from The Cancer Genome Atlas 
(TCGA), were based on data generated using Human Methylation 450 BeadChips (Illumina). The results were 
downloaded from the Broad Institute GDAC Firehose (http://gdac.broadinstitute.org/), and used in compliance 
with TCGA’s data usage policy.
Data Availability
All data generated or analysed during this study are included in this published article and its supplementary in-
formation files. The whole-genome expression data had been deposited in the Gene Expression Omnibus (GEO) 
database (GSE102986).
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